Skip to main content
. Author manuscript; available in PMC: 2019 Aug 12.
Published in final edited form as: Cell Rep. 2019 Apr 9;27(2):631–647.e5. doi: 10.1016/j.celrep.2019.03.045

Figure 6. GDC0941 and VCR Treatment Synergy in 28 Cell Lines of 5 Different Cancer Types.

Figure 6.

(A) Selection of 28 cell lines from 5 different cancers to be tested for GDC0941 and vincristine synergy.

(B) Robotics-generated 8 × 8 grids allowed for the analysis of synthetic lethality byGDC0941 and vincristine (VCR) on 10humanT-ALLcell lines; grids for growth and synergy shown for JURKAT cells (left), along with summary for the 10 best ΔBliss values for all of the lines tested (right).

(C–F) Same as (B), but for breast cancer (C), colorectal cancer (D), glioblastoma (E), and pancreatic cancer (F), each with 1 selected cell line highlighted and summary plots for the other lines tested.

(G) Phospho-flow analysis of baseline (black) phospho-Akt (top) and phospho-S6 (bottom) levels, and treatment with GDC0941 (blue), second inhibitor alone (orange), or a combination of both (red) (n = 2).

(H) Same as (G), but with treatment with IPI145 (blue).

(G) and (H) are representative examples of ≥3 independent experiments (n = 2).